Stavudine
Mostrando 13-24 de 88 artigos, teses e dissertações.
-
13. Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
Antiretroviral therapy has been associated with hyperlipidemia in AIDS patients. This case illustrates the classic metabolic effects associated to the HAART including protease inhibitors and/or stavudine. It was showed that the management of the HAART-associated dyslipidaemia with conventional antihyperlipidemic therapy may fail, being the switching strategy
Brazilian Journal of Infectious Diseases. Publicado em: 2007-04
-
14. Cytokine profile and clinical metabolic alterations in HIV-1 infected individuals with and without lipodistrophy
The extensive use of Highly Active Antiretroviral Therapy (HAART) has transformed HIV infection into a chronic condition. Thus, metabolic alterations including lipodystrophy and dyslipidemia have been associated with the use of such medications. The objective of the present study was to analyze clinical metabolic alterations and the profile of TNF-alpha, IFN
Journal of Venomous Animals and Toxins including Tropical Diseases. Publicado em: 2007
-
15. Determinação de lamivudina, estavudina e nevirapina, em comprimidos, por cromatografia líquida de alta eficiência
A high performance liquid chromatography method was developed to quantify lamivudine, stavudine and nevirapine combined in tablets. The separation was carried out in less than 10 min using a phosphate buffer of pH 3.0 and acetonitrile (75:25, v/v) as mobile phase, a LiChrospher ODS column and UV detection at 266 nm. The method was linear over the range of 15
Química Nova. Publicado em: 2006-12
-
16. Stability-indicating methods for quantitative determination of zidovudine and stavudine in capsules
Zidovudine (AZT) and stavudine (D4T) are nucleoside reverse transcriptase inhibitors extensively used in human immunodeficiency virus (HIV) infected patients. In order to evaluate the quality of these drugs, two stability indicating HPLC methods were developed. The validated methods were applied in quantitative determination of AZT, D4T and their induced deg
Química Nova. Publicado em: 2006-04
-
17. AIDS-associated diarrhea and wasting in northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum
Advanced HIV infection is frequently complicated by diarrhea, disruption of bowel structure and function, and malnutrition. Resulting malabsorption of or pharmacokinetic changes in antiretroviral agents might lead to subtherapeutic drug dosing and treatment failure in individual patients, and could require dose adjustment and/or dietary supplements during pe
Brazilian Journal of Infectious Diseases. Publicado em: 2003-02
-
18. Validation of analytical methods for analysis and stability studies of anti-retrovirais in pharmaceutical preparations. / Validação de métodos para análise e estudos de estabilidade de anti-retrovirais em preparações farmacêuticas
The acquired immunodeficiency syndrome is characterized by causing physical and functional depletion of the organisms immune system, through the cytophatic infection of CD4+ cells. Several antiretroviral drugs has been developed and commercially made available. In order to assure the quality control of drugs it is necessary to develop and validate new anal
Publicado em: 2003
-
19. Estratégias farmacológicas para a terapia anti-AIDS
The replicative cycle of HIV presents several events. The proteins involved in these events can be anticipated as pharmacological targets, aiming to the development of anti viral agents. Presently, there are fifteen commercially available anti-HIV drugs, which act at substrate binding site of reverse transcriptase (zidovudine, didanosine, zalcitabine, stavud
Química Nova. Publicado em: 2002-12
-
20. Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2',3'-didehydro-3'-deoxythymidine) in the pigtailed macaque (Macaca nemestrina).
Stavudine (22 micrograms/min/kg of body weight) was infused alone (via the femoral vein) or simultaneously with zidovudine (66 micrograms/min/kg) to three near-term pregnant macaques. No significant differences were found between the mean steady-state plasma stavudine concentrations in the dam (Cssd) and fetus (Cssf), the stavudine concentration in the amnio
-
21. A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients
The effects of multiple opportunistic infection medications on stavudine pharmacokinetics were evaluated. Ten patients with CD4 counts of less than 200 cells/mm3 received stavudine (40 mg twice daily) in combination with one to three other drugs used to treat opportunistic infections. Serial blood samples for stavudine concentrations were collected after 1 w
American Society for Microbiology.
-
22. In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina).
To determine whether stavudine (2',3'-didehydro-3'-deoxythymidine) is actively transported in vivo across the placenta and to determine the extent of its transfer, stavudine was administered as an intravenous bolus to four near-term macaques (Macaca nemestrina) (5 mg/kg of body weight via the femoral vein) or to their fetuses (10 mg/kg via the carorid artery
-
23. Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.
Stavudine was administered (15 mg/kg of body weight) intravenously and orally to two monkeys in a randomized crossover study. Plasma and urine samples were analyzed for stavudine by high-performance liquid chromatography, and pharmacokinetic parameters were derived by a noncompartmental method. Total body clearance of stavudine was 0.64 liters/h/kg, with a s
-
24. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.
The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2',3'-dideoxy-3'-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex (ARC) enrolled in phase I and phase I/II dose-ranging trials. Each patient underwent inpatient pharmacokinetic studies following administration of the first oral stavudine dose; 59 patien